APOE and early-onset autosomal dominant Alzheimer disease: In neurodegenerative disease therapy, liposomes conjugated with a modified ApoE-derived peptide were developed to target Aβ aggregates, facilitating drug delivery for Alzheimer’s disease treatment [18].